Current Hematologic Malignancy Reports

, Volume 12, Issue 3, pp 217–226 | Cite as

A Review of Autologous Stem Cell Transplantation in Lymphoma

  • Umar Zahid
  • Faisal Akbar
  • Akshay Amaraneni
  • Muhammad Husnain
  • Onyee Chan
  • Irbaz Bin Riaz
  • Ali McBride
  • Ahmad Iftikhar
  • Faiz AnwerEmail author
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (D Persky, Section Editor)
Part of the following topical collections:
  1. Topical Collection on B-cell NHL, T-cell NHL, and Hodgkin Lymphoma


Purpose of Review

Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients.

Recent Findings

There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL.


Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting.


High-dose chemotherapy Autologous stem cell transplantation Relapsed/refractory Lymphoma Salvage chemotherapy Novel agents 



This work was supported by grant P30 CA023074 from the National Cancer Institute, National Institutes of Health, Bethesda, MD.

Authors’ Contributions

UZ, FA, AA, MH, OC, IBR, AM, AI, and FAα designed the study. All coauthors searched for studies, extracted data, summarized results, developed the manuscript, helped with final edits, and wrote the paper. Ali McBride PharmD MS and Faiz Anwer MD FACP will share senior authorship for this manuscript, and FAα will serve as corresponding author.

Compliance With Ethical Standards

Conflict of Interest

Umar Zahid, Faisal Akbar, Akshay Amaraneni, Muhammad Husnain, Onyee Chan, Irbaz Bin Riaz, Ali McBride, and Ahmad Iftikhar each declare no potential conflicts of interest.

Faiz Anwer reports grants from the National Cancer Institute and National Institutes of Health.

Human and Animal Rights

This article does not contain any data involving human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.CrossRefPubMedGoogle Scholar
  3. 3.
    Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(12):2004–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, et al. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix). BMC Cancer. 2016;16:282.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Arakelyan N, Berthou C, Desablens B, de Guibert S, Delwail V, Moles MP, et al. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group. Cancer. 2008;113(12):3323–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. J Clin Oncol. 2003;21(12):2320–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Morschhauser F, Brice P, Ferme C, Divine M, Salles G, Bouabdallah R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008;26(36):5980–7.CrossRefPubMedGoogle Scholar
  10. 10.
    d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, et al. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015;21(5):855–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Columbia University. Autologous and allogeneic transplant for relapsed lymphoma. In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[January 14.
  13. 13.
    Yun S, Vincelette ND, Abraham I, Puvvada S, Anwer F. Outcome comparison of allogeneic versus autologous stem cell transplantation in transformed low-grade lymphoid malignancies: a systematic review and pooled analysis of comparative studies. Acta Haematol. 2016;136(4):244–55.CrossRefPubMedGoogle Scholar
  14. 14.
    Fred Hutchinson Cancer Research Center. Autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treatment patients with high-risk Hodgkin lymphoma N-HL, multiple myeloma, or chronic lymphocytic leukemia. In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[January 14, 2017]. Available from:.
  15. 15.
    Taverna JA, Yun S, Jonnadula J, Saleh A, Riaz IB, Abraham I, et al. Role of maintenance therapy after high-dose chemotherapy and autologous hematopoietic cell transplantation in aggressive lymphomas: a systematic review. Biol Blood Marrow Transplant. 2016;22(7):1182–96.CrossRefPubMedGoogle Scholar
  16. 16.
    Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016.Google Scholar
  17. 17.
    Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015;14:207.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758–65.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. . ASH 58th Annual Meeting & Exposition; December 3–6, 2016; San Diego, CA, 2016.Google Scholar
  21. 21.
    Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369(18):1681–90.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia. 2007;21(8):1802–11.CrossRefPubMedGoogle Scholar
  23. 23.
    Vitolo U, Chiappella A, Angelucci E, Rossi G, Liberati AM, Cabras MG, et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica. 2009;94(9):1250–8.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kim YR, Kim SJ, Cheong JW, Yang DH, Lee H, Eom HS, et al. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. Ann Hematol. 2016;95(9):1491–501.CrossRefPubMedGoogle Scholar
  25. 25.
    Kaneko H, Tsutsumi Y, Fujino T, Kuwahara S, Ohshiro M, Iwai T, et al. Favorable event free-survival of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for higher risk diffuse large B-cell lymphoma in first complete remission. Hematol Rep. 2015;7(2):5812.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Chiappella A, Castellino A, Vitolo U. State-of-the-art therapy for advanced-stage diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2016;30(6):1147–62.CrossRefPubMedGoogle Scholar
  27. 27.
    Iams W, Reddy NM. Consolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspective. Ther Adv Hematol. 2014;5(5):153–67.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14(Suppl 1):i5–10.CrossRefPubMedGoogle Scholar
  30. 30.
    Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103(10):3684–8.CrossRefPubMedGoogle Scholar
  31. 31.
    • Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490–6. This randomized study including over 600 patients showed the salvage chemotherapy regimen GDP before ASCT to be non-inferior and had less toxicities compared to the standard DHAP regimen for R/R DLBCL CrossRefPubMedGoogle Scholar
  32. 32.
    El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18(8):1363–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29(31):4079–87.CrossRefPubMedGoogle Scholar
  34. 34.
    Kondo E. Autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma. J Clin Exp Hematop. 2016;56(2):100–8.CrossRefPubMedGoogle Scholar
  35. 35.
    • Chen YB, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf MD, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046–53. Large study including almost 5000 patients from the CIBMTR database found patients undergoing HDT with ASCT who received high-dose CBV conditioning regimen had worse outcomes compared to other regimens CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31(13):1662–8.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Auger-Quittet S, Duny Y, Daures JP, Quittet P. Outcomes after (90) yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis. Cancer Med. 2014;3(4):927–38.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–61.CrossRefPubMedGoogle Scholar
  39. 39.
    Landsburg DJ, et al. Benefit of consolidative autologous stem cell transplantation in first complete remission for patients with double hit lymphoma appears dependent on induction regimen intensity. (2016): 3455–3455.Google Scholar
  40. 40.
    Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677–84.CrossRefPubMedGoogle Scholar
  41. 41.
    Hoster E, Metzner B, Forstpointner R, Pfreundschuh M, Trumper L, Hallek M, et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood. 2009;114(22):362–3.Google Scholar
  42. 42.
    Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–75.CrossRefPubMedGoogle Scholar
  43. 43.
    Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158(3):355–62.CrossRefPubMedGoogle Scholar
  44. 44.
    Connors JM. State-of-the-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol. 2005;23(26):6400–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Ansell SM. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(4):434–42.CrossRefPubMedGoogle Scholar
  46. 46.
    Strauss DJGJ, Myers J, Merke DP, Caravelli J, Chapman D, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990;8:1173–86.CrossRefGoogle Scholar
  47. 47.
    Carella AM, Bellei M, Brice P, Gisselbrecht C, Visani G, Colombat P, et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results. Haematologica. 2009;94(1):146–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934–7.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    • von Tresckow B, Moskowitz CH. Treatment of relapsed and refractory Hodgkin lymphoma. Semin Hematol. 2016;53(3):180–5. Comprehensive review of current advancement in Hodgkin Lymphoma CrossRefGoogle Scholar
  50. 50.
    Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–23.CrossRefPubMedGoogle Scholar
  51. 51.
    Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35–41.CrossRefPubMedGoogle Scholar
  53. 53.
    Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–4.CrossRefPubMedGoogle Scholar
  54. 54.
    Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013;6:CD009411.Google Scholar
  55. 55.
    Reece DE, Nevill TJ, Sayegh A, Spinelli JJ, Brockington DA, Barnett MJ, et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease. Bone Marrow Transplant. 1999;23(11):1131–8.CrossRefPubMedGoogle Scholar
  56. 56.
    Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, et al. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin’s lymphoma. Bone Marrow Transplant. 2008;41(7):613–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, et al. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2010;16(8):1145–54.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, et al. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. Br J Haematol. 2016;172(1):111–21.CrossRefPubMedGoogle Scholar
  59. 59.
    Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marcais A, et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica. 2016;101(4):474–81.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Moskowitz AJ, Schoder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284–92.CrossRefPubMedGoogle Scholar
  61. 61.
    Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, et al. Results of a multicenter phase II trial of Brentuximab Vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136–40.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62.CrossRefPubMedGoogle Scholar
  63. 63.
    Ansell SM. Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res. 2016.Google Scholar
  64. 64.
    Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Moskowitz Cea. PD-1 blockade with the monoclonal antibody pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Preliminary results from a phase 1b study presented at the 56th meeting of the American Society for Hematology; December 2014; San Francisco, CA.Google Scholar
  66. 66.
    Armand P TJ, et al. Nivolumab in patients (Pts) with relapsed or refractory classical Hodgkin lymphoma (R/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039). . Blood 2015; 126(23): 583 [Oral and Poster Abstracts])Google Scholar
  67. 67.
    Armand P SM, Ribrag V, et al. . PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: safety, efficacy, and biomarker assessment. Preliminary results presented at the 57th meeting of the American Society for Hematology; 2015; Orlando, FL.Google Scholar
  68. 68.
    Moskowitz CH, Zinzani PL, Fanale MA, Armand P, Johnson NA, Radford JA, et al. Pembrolizumab in relapsed/refractory classical Hodgkin lymphoma: primary end point analysis of the phase 2 Keynote-087 Study. Blood. 2016;128(22).Google Scholar
  69. 69.
    Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)—a phase 2 study. Preliminary results presented at the meeting of the American Society for Clinical Oncology; June 2016; Chicago, IL.Google Scholar
  70. 70.
    Chen RW ZP, Fanale MA et al. . Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. . 2016 ASCO Annual Meeting J Clin Oncol 34, (suppl; abstr 7555), 2016.Google Scholar
  71. 71.
    Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–94.CrossRefPubMedGoogle Scholar
  72. 72.
    Hatake K KT, Fukuhara N et al. . Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): an interim analysis. . 2016 ASCO Annual Meeting J Clin Oncol 34, 2016 (suppl; abstr e19018), 2016.Google Scholar
  73. 73.
    Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51(1):25–34.CrossRefPubMedGoogle Scholar
  74. 74.
    Dearden CE, Johnson R, Pettengell R, Devereux S, Cwynarski K, Whittaker S, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol. 2011;153(4):451–85.CrossRefPubMedGoogle Scholar
  75. 75.
    Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30.CrossRefPubMedGoogle Scholar
  76. 76.
    Sonnen R, Schmidt WP, Muller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol. 2005;129(3):366–72.CrossRefPubMedGoogle Scholar
  77. 77.
    Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151(2):159–66.CrossRefPubMedGoogle Scholar
  78. 78.
    Delmer A, et al. . Intensified induction therapy with etoposide (VP16) and high-dose cytarabine (Ara-C) in patients aged less than 60 years with peripheral T cell/NK lymphoma: preliminary results of the phase II GELA study LNH98T7. . in Proc Am Soc Clin Oncol 2003.Google Scholar
  79. 79.
    Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418–25.CrossRefPubMedGoogle Scholar
  80. 80.
    Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570–7.CrossRefPubMedGoogle Scholar
  81. 81.
    Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106–13.CrossRefPubMedGoogle Scholar
  82. 82.
    • Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014;28(9):1885–91. A prospective trial studying the role of high dose chemo-immunotherapy with and without stem cell transplant in T cell Lymphoma CrossRefPubMedGoogle Scholar
  83. 83.
    Choi I, Tanosaki R, Uike N, Utsunomiya A, Tomonaga M, Harada M, et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials. Bone Marrow Transplant. 2011;46(1):116–8.CrossRefPubMedGoogle Scholar
  84. 84.
    Parovichnikova EN, Kuz’mina LA, Mendeleeva LP, Kliasova GA, Troitskaia VV, Sokolov AN, et al. Autologous hematopoietic stem cell transplantation as late high-dose consolidation in adult patients with T-cell lymphoblastic leukemias: results of a Russian multicenter study. Ter Arkh. 2015;87(7):15–25.CrossRefPubMedGoogle Scholar
  85. 85.
    Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: peripheral T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99:214–27.CrossRefPubMedGoogle Scholar
  86. 86.
    Malik SM, Liu K, Qiang X, Sridhara R, Tang S, McGuinn Jr WD, et al. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2010;16(20):4921–7.CrossRefPubMedGoogle Scholar
  87. 87.
    A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas. Clin Adv Hematol Oncol. 2014;12(2 Suppl 6):3–4.Google Scholar
  88. 88.
    Makita S TK. Clinical features and current optimal management of natural killer/T-cell lymphoma. Hematology/Oncology Clinics of North America. 2017.Google Scholar
  89. 89.
    Yun S, Taverna JA, Puvvada SD, Anwer F. NK/T-cell non-Hodgkin’s lymphoma with secondary haemophagocytic lymphohistiocytosis treated with matched unrelated donor allogeneic stem cell transplant. BMJ Case Rep. 2014;2014.Google Scholar
  90. 90.
    Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118(12):3419–25.CrossRefPubMedGoogle Scholar
  91. 91.
    Ramzi M, Mohamadian M, Vojdani R, Dehghani M, Nourani H, Zakerinia M, et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant. 2012;10(2):163–7.CrossRefPubMedGoogle Scholar
  92. 92.
    Falzetti F, Di Ianni M, Ballanti S, Iodice G, Reale A, Minelli O, et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clin Exp Med. 2012;12(3):165–71.CrossRefPubMedGoogle Scholar
  93. 93.
    • Mounier N, Gill D, Linch D, Trneny M, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2016. Three independent factors (low to low-intermediate tIPI at relapse, progression > 6 months from ASCT, and chemosensitivities) predictive of improved outcomes were found using the famous CORAL cohort data for patients relapsed after autologous stem cell transplantation. Google Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Umar Zahid
    • 1
    • 2
  • Faisal Akbar
    • 3
  • Akshay Amaraneni
    • 4
  • Muhammad Husnain
    • 5
  • Onyee Chan
    • 5
  • Irbaz Bin Riaz
    • 1
  • Ali McBride
    • 6
  • Ahmad Iftikhar
    • 7
  • Faiz Anwer
    • 8
    • 9
    Email author
  1. 1.Department of MedicineUniversity of ArizonaTucsonUSA
  2. 2.College of Public HealthUniversity of ArizonaTucsonUSA
  3. 3.Department of MedicineWake Forest Baptist Medical CenterWinston SalemUSA
  4. 4.Department of Medicine, Hematology and OncologyUniversity of ArizonaTucsonUSA
  5. 5.Internal medicine Residency program, Department of MedicineUniversity of ArizonaTucsonUSA
  6. 6.College of PharmacyUniversity of ArizonaTucsonUSA
  7. 7.Department of Hematology and OncologyUniversity of ArizonaTucsonUSA
  8. 8.Department of medicine, Hematology Oncology and Arizona Cancer CenterUniversity of ArizonaTucsonUSA
  9. 9.Department of Medicine, Division of Hematology, Oncology, Blood & Marrow Transplantation, Multiple Myeloma ProgramUniversity of ArizonaTucsonUSA

Personalised recommendations